References
1. Boisson-Dupuis S, Kong XF, Okada S, Cypowyj S, Puel A, Abel L, et al.
Inborn errors of human STAT1: allelic heterogeneity governs the
diversity of immunological and infectious phenotypes. Curr Opin Immunol.
2012;24(4):364-78.
2. Zimmerman O, Rosler B, Zerbe CS, Rosen LB, Hsu AP, Uzel G, et al.
Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal
Disease. Open Forum Infect Dis. 2017;4(4):ofx202.
3. Aldave Becerra JC, Cachay Rojas E. A 3-Year-Old Girl with Recurrent
Infections and Autoimmunity due to a STAT1 Gain-of-Function Mutation:
The Expanding Clinical Presentation of Primary Immunodeficiencies. Front
Pediatr. 2017;5:55.
4. Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, Aldave
Becerra JC, et al. Heterozygous STAT1 gain-of-function mutations
underlie an unexpectedly broad clinical phenotype. Blood.
2016;127(25):3154-64.
5. Al Shehri T, Gilmour K, Gothe F, Loughlin S, Bibi S, Rowan AD, et al.
Novel Gain-of-Function Mutation in Stat1 Sumoylation Site Leads to
CMC/CID Phenotype Responsive to Ruxolitinib. J Clin Immunol.
2019;39(8):776-85.
6. Kiykim A, Charbonnier LM, Akcay A, Karakoc-Aydiner E, Ozen A, Ozturk
G, et al. Hematopoietic Stem Cell Transplantation in Patients with
Heterozygous STAT1 Gain-of-Function Mutation. J Clin Immunol.
2019;39(1):37-44.
7. Naviglio S, Soncini E, Vairo D, Lanfranchi A, Badolato R, Porta F.
Long-Term Survival After Hematopoietic Stem Cell Transplantation for
Complete STAT1 Deficiency. J Clin Immunol. 2017;37(7):701-6.